Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Novogene Co., Ltd. (688315.SS)
Beijing, CN
Novogene Co., Ltd. is a global provider of comprehensive genomic services and advanced solutions. Its offerings span a wide array of genomic applications, including human, animal, plant, and microbial genome sequencing, alongside gene regulation and single-cell sequencing technologies. The company also specializes in cancer genomic profiling, whole exome sequencing (including clinical-grade versions), and FFPE RNA sequencing. Furthermore, Novogene develops proprietary tools such as NovoFocus, a next-generation sequencing (NGS)-based companion diagnostic for PARP inhibitor treatments, and NovoNeoantigen, a bioinformatics pipeline that identifies cancer neoantigens by analyzing whole exome and whole transcriptome sequencing data from matched tumor and normal samples. In a strategic collaboration, Novogene partners with Hummingbird Bioscience Pte. Ltd. to aid in the advancement of HMBD-001. This investigational anti-HER3 antibody is being assessed for its potential to treat diverse cancer types, notably those driven by NRG1-fusion. Established in 2011, Novogene Co., Ltd. operates from its headquarters in Beijing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.10% | -4.01% | -0.63% | -7.94% | +3.29% | +6.48% | +1.95% | -54.46% | -75.92% | -48.39% | -48.39% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+4.7% ★ Q1'26: +10.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-14.6% Q1'26: -12.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+5.4% Q1'26: -26.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+8.8% ★ Q1'26: +7.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+18.1% ★ Q1'26: +11.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-1.2% ★ Q1'26: -0.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.11× ★ Q1'26: 0.19× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
1.87B
est: 1.87B (+0.0%)
|
1.93B
est: 1.98B (-2.6%)
|
2.00B
est: 2.07B (-3.2%)
|
2.11B
est: 2.14B (-1.4%)
|
2.21B
est: 2.20B (+0.3%)
|
2.45B
2.44B – 2.46B
+11.2% YoY
|
2.72B
2.71B – 2.73B
+10.8% YoY
|
3.00B
2.98B – 3.02B
+10.5% YoY
|
| EBITDA |
366.29M
est: 321.19M (+14.0%)
|
322.76M
est: 340.43M (-5.2%)
|
343.60M
est: 356.55M (-3.6%)
|
360.21M
est: 368.98M (-2.4%)
|
343.84M
est: 379.84M (-9.5%)
|
422.51M
420.62M – 424.41M
+11.2% YoY
|
468.20M
466.65M – 470.43M
+10.8% YoY
|
517.25M
514.35M – 520.16M
+10.5% YoY
|
| EBIT |
249.38M
est: 182.92M (+36.3%)
|
210.70M
est: 193.88M (+8.7%)
|
216.18M
est: 226.32M (-4.5%)
|
227.65M
est: 234.21M (-2.8%)
|
193.52M
est: 241.10M (-19.7%)
|
268.19M
266.99M – 269.39M
+11.2% YoY
|
297.19M
296.21M – 298.61M
+10.8% YoY
|
328.33M
326.49M – 330.17M
+10.5% YoY
|
| Net Income |
225.20M
est: 231.64M (-2.8%)
|
177.23M
est: 194.74M (-9.0%)
|
178.06M
est: 177.91M (+0.1%)
|
196.79M
est: 190.52M (+3.3%)
|
166.11M
est: 182.41M (-8.9%)
|
206.63M
204.62M – 208.63M
+13.3% YoY
|
242.20M
240.86M – 243.54M
+17.2% YoY
|
281.05M
279.49M – 282.60M
+16.0% YoY
|
| SGA |
422.48M
est: 245.30M (+72.2%)
|
502.60M
est: 259.99M (+93.3%)
|
555.24M
est: 459.41M (+20.9%)
|
562.17M
est: 475.43M (+18.2%)
|
175.34M
est: 489.42M (-64.2%)
|
544.41M
541.97M – 546.85M
+11.2% YoY
|
603.27M
601.28M – 606.15M
+10.8% YoY
|
666.48M
662.74M – 670.22M
+10.5% YoY
|
| EPS |
0.58
est: 0.57 (+2.7%)
|
0.44
est: 0.48 (-7.4%)
|
0.44
est: 0.44 (+0.3%)
|
0.48
est: 0.47 (+2.1%)
|
0.41
est: 0.45 (-8.9%)
|
0.51
0.51 – 0.51
+13.3% YoY
|
0.60
0.59 – 0.60
+17.2% YoY
|
0.69
0.69 – 0.70
+16.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jiashan Shi | Financial Director | — | male |
| Qifeng Wang | Deputy GM, Secretary of the Board of Directors & Director | — | male |
| Ruiqiang Li | Founder, Chairman of the Board & Chief Executive Officer | — | — |
| Weisheng Chen | Accounting Supervisor | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688315.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
